What happened to drug trials in ulcerative colitis? Problems, PPARs, placebos, and (possible) progress

American Journal of Gastroenterology

Volumn 96, Issue 12, 2001, Pages 3232-3234

  Kornbluth, Asher ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Dr Henry D Janowitz Div G   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; HEPARIN; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; NICOTINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PLACEBO; ROSIGLITAZONE; STEROID; TROGLITAZONE;

CLINICAL TRIAL; COLONOSCOPY; CROHN DISEASE; DRUG MECHANISM; EDITORIAL; ENTERITIS; HUMAN; PRIORITY JOURNAL; SIGMOIDOSCOPY; ULCERATIVE COLITIS;

EID: 0035659680     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(01)03881-3     Document Type: Note

References (12)

1. Chronic intestinal diseases
2. Biologic therapy for inflammatory bowel disease
3. Current concepts of inflammatory bowel disease etiology and pathogenesis
4. An open-label trial of the PPARγ ligand rosiglitazone for active ulcerative colitis
5. A novel therapy for utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response
6. A multi-center, randomized, controlled trial of heparin for the treatment of acute ulcerative colitis
7. A randomized, double-blind, placebo controlled trial of hydroxychloroquine in the treatment of ulcerative colitis
8. A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis
9. Meta-analysis of the effectiveness of current drug therapy of ulcerative colitis
10. Quantification of the placebo response in ulcerative colitis
11. The placebo response and the "natural history" of inflammatory bowel disease
12. IBD and the "uncertainty principle"